ArticleInsights into imaging2022
Reappraising the clinical usability of consolidation-to-tumor ratio on CT in clinical stage IA lung cancer.
Article in Insights into imaging, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Multifocal ground-glass opacities in lung cancer: a narrative review of genomic evolution, immune ecology, and biology-informed clinical management.Journal of thoracic disease · 2026Review
- Is the consolidation-to-tumor ratio an independent prognostic factor in clinical T1 stage lung adenocarcinoma radiologically manifesting as a subsolid nodule?-a retrospective cohort study.Journal of thoracic disease · 2026Article
- Evaluating the value of circulating miR-21, miR-210 and miR-942 in the diagnosis of early-stage lung adenocarcinoma.BMC cancer · 2025Article
- Prognostic value of integrating CT morphological features and PET volumetric metabolic parameters in surgically resected stage IA non-small cell lung cancer: a two-center retrospective study.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- The Solid Volume Ratio is Better Than the Consolidation Tumor Ratio in Predicting the Malignant Pathological Features of cT1 Lung Adenocarcinoma.The Thoracic and cardiovascular surgeon · 2025Article
- Analysis of lymph node metastasis based on consolidation tumor ratio and maximum standardized uptake value in clinical stage IA non-small cell lung cancer.Journal of thoracic disease · 2025Article
- Enhancing Identification of High-Risk cN0 Lung Adenocarcinoma Patients Using MRI-Based Radiomic Features.Cancer research and treatment · 2025Article
- CT radiomics combined with neural networks predict the malignant degree of pulmonary grinding glass nodules.Frontiers in medicine · 2025Article
- Choice of wedge resection for selected T1a/bN0M0 non-small cell lung cancer.Scientific reports · 2024Article
- CTR > 0.7 predicts the subgroup of lung adenocarcinomas ≤ 2 cm at risk of poor outcome treated by sublobar resection compared to lobar resection.Cancer imaging : the official publication of the International Cancer Imaging Society · 2024Article
- Construction of a predictive model of 2-3 cm ground-glass nodules developing into invasive lung adenocarcinoma using high-resolution CT.Frontiers in medicine · 2024Article
- The solid component within part-solid nodules: 3-dimensional quantification, correlation with the malignant grade of nonmucinous pulmonary adenocarcinomas, and comparisons with 2-dimentional measures and semantic features in low-dose computed tomography.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Tumor size, but not consolidation-to-tumor ratio, is an independent prognostic factor for part-solid clinical T1 non-small cell lung cancer.Thoracic cancer · 2023Review
- A rare case report: co-occurrence of two types of lung cancer with hamartoma and pulmonary tuberculosis.Frontiers in oncology · 2023Article
- Correlation between gene mutation status and clinicopathologic features in early multiple primary lung cancer.Frontiers in oncology · 2023Article
- Distinct Prognostic Factors of Ground Glass Opacity and Pure-Solid Lesion in Pathological Stage I Invasive Lung Adenocarcinoma.World journal of oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesGround-glass opacity (GGO) on computed tomography is associated with prognosis in early-stage non-small cell lung cancer (NSCLC) patients. However, the stratification of the prognostic value of GGO is controversial. We aimed to evaluate clinicopathologic characteristics of early-stage NSCLC based on the consolidation-to-tumor ratio (CTR), conduct multi-pronged analysis, and stratify prognosis accordingly.
methodsWe retrospectively investigated 944 patients with clinical stage IA NSCLC, who underwent curative-intent lung resection between August 2018 and January 2020. The CTR was measured and used to categorize patients into six groups (1, 0%; 2, 0-25%; 3, 25-50%; 4, 50-75%; 5, 75-100%; and 6, 100%).
resultsPathologic nodal upstaging was found in 1.8% (group 4), 9.0% (group 5), and 17.4% (group 6), respectively. The proportion of patients with a high grade of tumor-infiltrating lymphocytes tended to decrease as the CTR increased. In a subtype analysis of patients with adenocarcinoma, all of the patients with predominant micro-papillary patterns were in the CTR > 50% groups, and most of the patients with predominant solid patterns were in group 6 (47/50, 94%). The multivariate analysis demonstrated that CTR 75-100% (hazard ratio [HR], 3.85; 95% confidence interval [CI], 1.58-9.36) and CTR 100% (HR, 5.58; 95% CI, 2.45-12.72) were independent prognostic factors for DFS, regardless of tumor size.
conclusionWe demonstrated that the CTR could provide various noninvasive clinicopathological information. A CTR of more than 75% is the factor associated with a poor prognosis and should be considered when making therapeutic plans for patients with early-stage NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.